Jubilant Pharmova Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹1022.60
Market cap
16,157 Cr
Stock P/E
46.1
P/B
2.28
Dividend yield
0.5%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,587 Cr | 3,267 Cr | 4,944 Cr | 6,703 Cr | 1,732 Cr | 3,484 Cr | 1,822 Cr | 1,929 Cr | 1,901 Cr | 1,966 Cr | 2,123 Cr | 2,290 Cr |
| Operating expenses (approx.) | 1,409 Cr | 2,837 Cr | 4,261 Cr | 5,902 Cr | 1,070 Cr | 2,526 Cr | 1,544 Cr | 1,575 Cr | 1,599 Cr | 1,621 Cr | 1,852 Cr | 1,941 Cr |
| EBITDA | 178 Cr | 430 Cr | 684 Cr | 801 Cr | 661 Cr | 958 Cr | 278 Cr | 354 Cr | 302 Cr | 345 Cr | 270 Cr | 349 Cr |
| OPM % | 11.2% | 13.2% | 13.8% | 11.9% | 38.2% | 27.5% | 15.2% | 18.4% | 15.9% | 17.6% | 12.7% | 15.3% |
| Other income | 9 Cr | 19 Cr | 54 Cr | 69 Cr | 14 Cr | 36 Cr | 9 Cr | 12 Cr | 12 Cr | 10 Cr | 21 Cr | 24 Cr |
| Interest | 62 Cr | 128 Cr | 199 Cr | 272 Cr | 71 Cr | 132 Cr | 56 Cr | 53 Cr | 49 Cr | 50 Cr | 56 Cr | 57 Cr |
| Depreciation | 90 Cr | 186 Cr | 281 Cr | 382 Cr | 91 Cr | 182 Cr | 91 Cr | 95 Cr | 98 Cr | 105 Cr | 121 Cr | 117 Cr |
| Profit before tax | 27 Cr | 116 Cr | 204 Cr | 146 Cr | 500 Cr | 644 Cr | 131 Cr | 206 Cr | 155 Cr | 190 Cr | 94 Cr | 176 Cr |
| Tax % | 72.2% | 47.7% | 44.1% | 66.8% | 3.6% | 9.3% | 22.8% | 26.5% | 33.6% | 37.0% | 40.2% | 32.2% |
| Net profit | 6 Cr | 68 Cr | 135 Cr | 73 Cr | 482 Cr | 584 Cr | 101 Cr | 151 Cr | 103 Cr | 120 Cr | 56 Cr | 119 Cr |
| EPS (₹) | ₹0.40 | ₹4.34 | ₹8.56 | ₹4.87 | ₹30.44 | ₹36.91 | ₹6.37 | ₹9.71 | ₹6.49 | ₹7.59 | ₹3.52 | ₹7.55 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 9,111 Cr | 9,154 Cr | 6,099 Cr | 6,059 Cr | 6,282 Cr | 670 Cr | 7,235 Cr | 8,280 Cr | Sign in for TTM |
| Operating expenses (approx.) | 7,652 Cr | 7,195 Cr | 4,706 Cr | 4,892 Cr | 5,562 Cr | 597 Cr | 5,645 Cr | 7,013 Cr | Sign in for TTM |
| EBITDA | 1,459 Cr | 1,960 Cr | 1,393 Cr | 1,168 Cr | 719 Cr | 73 Cr | 1,590 Cr | 1,267 Cr | Sign in for TTM |
| OPM % | 16.0% | 21.4% | 22.8% | 19.3% | 11.5% | 10.9% | 22.0% | 15.3% | Sign in for TTM |
| Other income | 36 Cr | 47 Cr | 18 Cr | 82 Cr | 38 Cr | 7 Cr | 57 Cr | 66 Cr | Sign in for TTM |
| Interest | 220 Cr | 287 Cr | 184 Cr | 145 Cr | 188 Cr | 27 Cr | 240 Cr | 212 Cr | Sign in for TTM |
| Depreciation | 371 Cr | 462 Cr | 349 Cr | 382 Cr | 554 Cr | 38 Cr | 369 Cr | 440 Cr | Sign in for TTM |
| Profit before tax | 904 Cr | 1,211 Cr | 860 Cr | 640 Cr | 16 Cr | 15 Cr | 981 Cr | 614 Cr | Sign in for TTM |
| Tax % | 36.2% | 25.8% | 34.6% | 34.0% | 596.7% | 66.8% | 14.7% | 35.3% | Sign in for TTM |
| Net profit | 577 Cr | 898 Cr | 836 Cr | 413 Cr | -65 Cr | 7 Cr | 836 Cr | 398 Cr | Sign in for TTM |
| EPS (₹) | ₹36.86 | ₹56.39 | ₹52.48 | ₹26.00 | ₹-3.83 | ₹4.87 | ₹52.99 | ₹25.15 | Sign in for TTM |
| Dividend payout % | — | — | — | 19.4% | — | 109.8% | 9.5% | 20.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 Cr | 16 Cr | 16 Cr | 16 Cr | 16 Cr | 2 Cr | 16 Cr | 16 Cr |
| Reserves | 4,793 Cr | 5,588 Cr | 4,726 Cr | 5,303 Cr | 5,383 Cr | 542 Cr | 6,239 Cr | 7,077 Cr |
| Borrowings | 4,743 Cr | — | — | — | 3,410 Cr | 341 Cr | 287 Cr | 248 Cr |
| Other liabilities | 1,917 Cr | 6,918 Cr | 4,177 Cr | 4,672 Cr | 2,355 Cr | 271 Cr | 6,231 Cr | 8,179 Cr |
| Total liabilities | 11,469 Cr | 12,522 Cr | 8,918 Cr | 9,991 Cr | 11,157 Cr | 1,155 Cr | 12,756 Cr | 15,523 Cr |
| Fixed assets (net) | 3,396 Cr | — | — | — | 2,298 Cr | 216 Cr | 2,132 Cr | 3,510 Cr |
| CWIP | 492 Cr | — | — | — | 773 Cr | 125 Cr | 2,715 Cr | 2,962 Cr |
| Investments | 115 Cr | — | — | — | 33 Cr | 3 Cr | 36 Cr | 61 Cr |
| Other assets | 4,588 Cr | — | — | — | 3,764 Cr | 363 Cr | 3,511 Cr | 4,111 Cr |
| Total assets | 11,469 Cr | 12,522 Cr | 8,918 Cr | 9,991 Cr | 11,157 Cr | 1,155 Cr | 12,756 Cr | 15,523 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 838 Cr | 661 Cr | 97 Cr | 1,072 Cr | 1,227 Cr |
| Cash from investing | — | — | — | -380 Cr | -544 Cr | -61 Cr | 488 Cr | -1,260 Cr |
| Cash from financing | — | — | — | -33 Cr | -157 Cr | -43 Cr | -1,453 Cr | 95 Cr |
| Net cash flow | — | — | — | 425 Cr | -40 Cr | -7 Cr | 132 Cr | 179 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 238 Cr | -154 Cr | 7 Cr | -43 Cr | -222 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 11.4% | 26.7% | 22.0% | 14.8% | 1.9% | 4.0% | 18.7% | 11.3% |
| ROE % | 11.9% | 16.0% | 17.6% | 7.8% | -1.1% | 1.4% | 13.5% | 5.6% |
| Debtor days | 51 | — | — | — | 56 | 50 | — | — |
| Inventory days | 157 | — | — | — | 302 | 258 | 207 | 193 |
| Days payable | 113 | — | — | — | 179 | 172 | — | — |
| Cash conversion cycle | 95 | — | — | — | 178 | 137 | 207 | 193 |
| Debt / equity | 0.99 | — | 0.00 | — | 0.63 | 0.63 | 0.05 | 0.03 |
| Current ratio | 2.19 | — | — | — | 2.12 | 1.92 | 1.62 | 1.62 |
| Net debt / EBITDA | 2.56 | 0.00 | 0.00 | 0.00 | 3.33 | 3.36 | -0.50 | -0.80 |
Compare with peers
Loading peers…